VIP (Vasoactive Intestinal Peptide): Research, Testing, and What the Evidence Shows

• VIP is a 28-amino-acid neuropeptide in the glucagon/secretin family.
• It is linked to the gut, immune system, blood vessels, and the brain’s clock center.
• Lab testing for plasma VIP is used to help assess VIP-secreting tumors such as VIPomas.
• Research has explored VIP in arthritis, gut disease, breathing, circadian rhythm, and other areas.

What VIP is

Vasoactive intestinal peptide, or VIP, is also called vasoactive intestinal polypeptide. It is a 28-amino-acid neuropeptide in the glucagon/secretin superfamily. In human biology, it is produced in many tissues, including the gut, pancreas, neocortex, and the suprachiasmatic nuclei of the hypothalamus. That makes it a signaling molecule with reach across several systems, not just the intestine.

VIP acts through class II G protein-coupled receptors. The research bundle names VPAC1 and VPAC2 as the main receptors tied to its effects. Across the sources provided, VIP is described as a peptide with vasoactive, smooth muscle, immune, and circadian roles. It has also been linked to neurobiology and sleep-wake timing.

In plain terms, VIP is not a one-purpose molecule. It appears in the gut, lungs, immune cells, and brain, where it helps shape how these systems communicate and respond.

Where VIP shows up in the body

Gut and digestive system

VIP has long been tied to digestive function. The provided PubMed study compared VIP and secretin in conscious dogs and found that VIP caused dose-related stimulation of basal pepsin output and inhibition of pentagastrin-induced acid secretion. It also inhibited acid response to histamine, which the study described as a broader spectrum of inhibition than secretin. In that work, VIP was considered one of the enterogastrones released in the small intestine.

The bundle also describes VIP as contributing to smooth muscle relaxation in the lower esophageal sphincter, stomach, and gallbladder, while stimulating secretion of water into pancreatic juice and bile. It is also linked with inhibition of gastric acid secretion and absorption from the intestinal lumen. These actions fit with a broader role in digestion and motility.

Lungs and airways

VIP is described in the research as a bronchodilator and pulmonary vasodilator. One source says it is the primary endogenous bronchodilator in the lungs. The same source links VIP-deficient states with pulmonary arterial hypertension and airway hyperresponsiveness. Another source cited in the bundle points to research on bioactive analogues and drug delivery systems of VIP for asthma and COPD.

That does not mean VIP is an established treatment for these conditions. It does mean the peptide has been studied because of its airway and vascular effects.

Brain and circadian timing

VIP is highly expressed in neurons of the suprachiasmatic nucleus, the brain region that helps set the body clock. A 2013 UAB summary reports that applying VIP to mouse slice cultures increased electrical activity in SCN neurons and that the effect lasted several hours after treatment. The summary says this points to a novel mechanism for long-term changes in central nervous system physiology.

In the provided research, VIP is linked to sleep-wake cycle maintenance and circadian rhythm entrainment. The UAB summary also notes that light therapy affects sleep and mood largely through the SCN, where VIP is part of the signaling network.

What the research says about immune and inflammatory effects

Much of the interest in VIP comes from inflammation research. A Johns Hopkins Arthritis summary of an animal study reported that VIP prevented or delayed experimentally induced arthritis in mice. In that model, VIP-treated mice had delayed onset, lower incidence, and less severe collagen-induced arthritis than placebo-treated mice.

The same summary lists several immune changes seen with VIP. These included inhibition of T-cell clonal expansion, lower Th1 cytokines such as interferon-gamma, higher Th2 cytokines such as IL-4, reduced type II collagen-specific IgG antibodies, a lower CD4:CD8 ratio in synovium, reduced inflammatory cytokines such as tumor necrosis factor and interleukin-1, and increased anti-inflammatory signals such as IL-10 and interleukin-1 receptor antagonist. It also notes suppression of MMP-2 gelatinase expression and activity.

That is a broad set of findings, but it is still animal research. The source itself says these results suggest VIP could be a candidate for clinical investigation in rheumatoid arthritis. It does not show that VIP is a proven therapy in people.

Why the immune data matter

The bundle includes a 2019 review title on a clinical approach to the VIP axis in inflammatory and autoimmune diseases, and a 2021 study on the mechanism of immunoregulatory properties of VIP in an autoimmune arthritis mouse model. Taken together with the Johns Hopkins summary, the research trend is clear: VIP is being studied as an immunoregulatory signal that may reduce inflammatory activity in preclinical settings.

One clinic-style source in the bundle also describes VIP as suppressing NF-kB activation and downstream cytokines like IL-6, TNF-alpha, IL-12, and MMP-9 while promoting IL-10 and TGF-beta1. Because this is not a primary study in the bundle, it should be read as a summary of a proposed mechanism rather than as proof on its own.

Testing VIP in the lab

Plasma VIP testing is listed by ARUP Lab as a test used to aid in diagnosis of vasoactive intestinal polypeptide secreting tumors, also called VIPomas. The test has a reference interval of 0-89.1 pg/mL. ARUP says the specimen should be collected in a chilled lavender or pink EDTA tube, placed on ice before centrifugation, and the plasma frozen at -20. It also lists specimen stability after separation as 4 hours at room temperature, 24 hours refrigerated, and 3 months frozen.

ARUP also notes that grossly hemolyzed, lipemic, icteric, or clotted specimens are unacceptable. These handling details matter because peptide assays are often sensitive to collection and transport conditions. In other words, the test is not just about drawing blood. The sample has to be handled the right way for the result to be useful.

This is one of the most concrete uses of VIP in current lab medicine: not as a wellness marker, but as a targeted test when a VIP-secreting tumor is being considered.

Clinical interest versus research interest

The research bundle points to several areas where VIP has been explored: inflammation, autoimmunity, gut disease, respiratory biology, diabetes, and brain timing systems. The sources also include a 2022 review on therapeutic potential of VIP and its receptor VPAC2 in type 2 diabetes, and a 2003 study on therapeutic effects of VIP in a mouse model of Crohn’s disease. Those topics show how wide the interest is, but they do not turn VIP into a general treatment claim.

There is an important distinction between mechanistic interest and clinical use. The bundle includes a wellness-oriented clinic page and a compounded nasal spray guide, but those are not the same as established drug approvals. One source in the bundle explicitly states that a VIP product is not an FDA-approved drug product and is not intended to diagnose, treat, cure, or prevent disease. That caution should stay front and center.

Why route and formulation matter

Because VIP is a peptide, delivery route matters. The bundle includes discussion of nasal spray and injectable forms in the context of compounded products, but it does not provide enough high-quality evidence here to support broad dosing or treatment claims. For research readers, the key point is that route, stability, and formulation are part of the practical challenge, not just the biology.

What is known, and what is not

What is known from the provided research is fairly consistent. VIP is a biologically active peptide with roles in smooth muscle relaxation, secretion, vasodilation, immune signaling, and circadian control. It is measurable in plasma, and abnormal elevations may help point toward VIPomas. It has also shown anti-inflammatory and immunomodulatory effects in animal studies, including arthritis models.

What is not known from the provided research is just as important. The sources do not establish VIP as a standard treatment for autoimmune disease, asthma, COPD, diabetes, or sleep disorders. They also do not support a general recommendation for use in healthy people. The evidence base shown here is a mix of physiology, animal work, lab testing, and early clinical interest.

That is a strong research profile, but not a finished clinical story.

How researchers may think about VIP

For researchers, VIP is best viewed as a signaling molecule with several overlapping systems in play. In the gut, it affects secretion and smooth muscle. In the lungs, it affects airway tone and pulmonary vessels. In the immune system, it can shift cytokine balance and lower inflammatory signaling in preclinical models. In the brain, it is tied to the circadian clock and can change neuronal firing for hours after exposure in mouse tissue.

This makes VIP useful for hypothesis building. It may help connect inflammation with nervous system signaling, or circadian biology with immune function. The sources also hint that the VIP axis may matter in diseases where multiple systems are disrupted at once. But the studies provided are not enough to claim a single unified clinical role.

For now, VIP remains a peptide with strong biology and selective clinical utility in testing, plus a large research footprint that continues to grow.

FAQ

What is VIP?

VIP stands for vasoactive intestinal peptide, also called vasoactive intestinal polypeptide. It is a 28-amino-acid neuropeptide found in the gut, pancreas, brain, lungs, and immune-related tissues.

What does VIP do in the body?

VIP helps regulate smooth muscle, secretion, blood vessel tone, immune signals, and circadian timing. The research bundle links it to digestion, bronchodilation, and the brain’s suprachiasmatic nucleus.

Why is plasma VIP tested?

Plasma VIP is tested to help diagnose VIP-secreting tumors, including VIPomas. ARUP lists a reference interval of 0-89.1 pg/mL and gives strict collection and handling rules for the assay.

Is VIP a proven treatment for autoimmune disease?

No. The provided research includes animal studies showing anti-inflammatory effects and arthritis benefits, but it does not establish VIP as a proven treatment in people.

Does VIP affect sleep or circadian rhythm?

Yes, the research bundle links VIP to the suprachiasmatic nucleus, the brain’s clock center. One mouse study summary says VIP increased SCN neural activity for several hours after treatment.

Is VIP an FDA-approved drug?

Not based on the sources provided here. One clinic source in the bundle states that a compounded VIP product is not an FDA-approved drug product and is not intended to diagnose, treat, cure, or prevent disease.